Blade Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Blade Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11095
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Blade Therapeutics Inc (Blade Therapeutics) is a biopharmaceutical company that develops novel anti-fibrotic therapies to treat various fibrotic disorders. The company’s lead program is a small molecule inhibitor targeting an intracellular cysteine protease associated with fibrosis across diverse indications. Its Blade conducts research and development programs to discover new drugs that modulate fibrosis-related diseases such as diabetic nephropathy (DN), idiopathic pulmonary fibrosis (IPF), non-alcoholic steatohepatitis (NASH). Blade Therapeutics offers services such as primary sclerosing cholangitis (PSC), systemic sclerosis (SSc), corneal fibrosis, and others. The company works in partnership with Scleroderma Research Foundation (SRF) to treat disorders of fibrosis, including scleroderma. Blade Therapeutics is headquartered in South San Francisco, California, the US.

Blade Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Blade Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Blade Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Blade Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Blade Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Blade Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Blade Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 10
Blade Therapeutics Raises USD27 Million in Series B Financing 12
Blade Therapeutics Raises USD6.5 Million in Series A Financing 14
Blade Therapeutics Raises Funds in Venture Financing 15
Licensing Agreements 16
Blade Therapeutics Enters into Licensing Agreement with Johns Hopkins University School of Medicine 16
Blade Therapeutics Inc – Key Competitors 17
Blade Therapeutics Inc – Key Employees 18
Blade Therapeutics Inc – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Corporate Communications 20
Feb 27, 2018: Blade Therapeutics Appoints Ryan Maynard As Chief Financial Officer 20
Jun 20, 2017: Blade Therapeutics Expands Leadership Team as Company Advances R&D Pipeline Addressing Fibrotic Diseases 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Blade Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Blade Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Blade Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Blade Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Blade Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Blade Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 10
Blade Therapeutics Raises USD27 Million in Series B Financing 12
Blade Therapeutics Raises USD6.5 Million in Series A Financing 14
Blade Therapeutics Raises Funds in Venture Financing 15
Blade Therapeutics Enters into Licensing Agreement with Johns Hopkins University School of Medicine 16
Blade Therapeutics Inc, Key Competitors 17
Blade Therapeutics Inc, Key Employees 18

List of Figures
Blade Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Blade Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Blade Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Blade Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Blade Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Blade Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Blade Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Blade Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Blade Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Vitasoy International Holdings Limited:企業の戦略・SWOT・財務情報
    Vitasoy International Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Vitasoy International Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • SurModics Inc (SRDX)-医療機器分野:企業M&A・提携分析
    Summary SurModics Inc (SurModics) is a provider of device drug delivery coating and in vitro diagnostic technologies. The company offers wide range of advanced technologies that includes medical device coating technologies and surface modification coating technologies. Its technologies are employed …
  • M1 Ltd:企業の戦略的SWOT分析
    M1 Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Gothaer Asigurari Reasigurari S.A.:企業の戦略・SWOT・財務情報
    Gothaer Asigurari Reasigurari S.A. - Strategy, SWOT and Corporate Finance Report Summary Gothaer Asigurari Reasigurari S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Golden Star Resources Ltd:企業の戦略・SWOT・財務分析
    Golden Star Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Golden Star Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • AltaGas Ltd (ALA)-石油・ガス分野:企業M&A・提携分析
    Summary AltaGas Ltd. (AltaGas), is an energy utility. The company undertakes activities related to extraction, transmission, distribution and storage of natural gas. AltaGas generates electricity utilizing diverse fuel sources, such as wind, run-of-river hydro, geothermal and gas-fired generation pl …
  • Omega Diagnostics Group Plc (ODX):企業の財務・戦略的SWOT分析
    Summary Omega Diagnostics Group Plc (Omega) is a biotechnology company that provides in-vitro diagnostic products. The company offers products in the areas of allergy, food intolerance, autoimmune disease and infectious disease, among others. It also provides food intolerance and autoimmune tests fo …
  • Dart Group PLC:企業の戦略・SWOT・財務情報
    Dart Group PLC - Strategy, SWOT and Corporate Finance Report Summary Dart Group PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Bluefish Pharmaceuticals AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Bluefish Pharmaceuticals AB (Bluefish Pharmaceuticals) is a pharmaceutical company that develops, manufactures and distributes generic pharmaceuticals. The company offers products in the therapeutic areas of cardiovascular, central nervous system, gastrointestinal, diabetes, oncology, dermat …
  • Warrnambool Cheese and Butter Factory Company Holdings Limited:企業の戦略・SWOT・財務情報
    Warrnambool Cheese and Butter Factory Company Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Warrnambool Cheese and Butter Factory Company Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report cov …
  • Sangoma Technologies Corporation (STC):企業の財務・戦略的SWOT分析
    Sangoma Technologies Corporation (STC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Huttig Building Products Inc:企業の戦略・SWOT・財務情報
    Huttig Building Products Inc - Strategy, SWOT and Corporate Finance Report Summary Huttig Building Products Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Charcot-Marie-Tooth Association:製薬・医療:M&Aディール及び事業提携情報
    Summary Charcot-Marie-Tooth Association (CMTA) is a healthcare service provider that offers healthcare services to patients suffering from charcot marie tooth disease. The association provides services such as public education, patient support, and research promotion. It offers services such as orth …
  • Mitsui Fudosan Co Ltd (8801):企業の財務・戦略的SWOT分析
    Mitsui Fudosan Co Ltd (8801) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • National Power Corporation:電力:M&Aディール及び事業提携情報
    Summary National Power Corporation (Napocor) is a government owned utility. It develops hydroelectric generation plants; produces power from nuclear, geothermal, and other sources; and transmits electricity across the country. The corporation preserves and protects the dams and watershed. Napocor’s …
  • GlobalSCAPE Inc (GSB):企業の財務・戦略的SWOT分析
    Summary GlobalSCAPE Inc (GlobalSCAPE) is a technology company that offers secure information exchange solutions. The company offers EFT platform products such as EFT enterprise, EFT express, public and private cloud, collaboration, automation and efficiency, protocols, security, compliance and analy …
  • Aptuit LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Aptuit LLC (Aptuit) is a developer and manufacturer of pharmaceutical drug. The company offers drug design and discovery, IND enabling programs, integrated chemistry, manufacture and control and indigo. It drug discovery capabilities includes medicinal chemistry, computational chemistry, pha …
  • Intellipharmaceutics International Inc (IPCI):企業の財務・戦略的SWOT分析
    Intellipharmaceutics International Inc (IPCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • SpectraCure AB (SPEC)-製薬・医療分野:企業M&A・提携分析
    Summary SpectraCure AB (SpectraCure) is a healthcare technology company that develops different methods for treatment planning and laser light dose management for cancer treatment. The company develops and therapy system (PDT) commercializes photodynamic with IDOSE for tumors. Its IDOSE platform all …
  • Pets at Home Group Plc:戦略・SWOT・企業財務分析
    Pets at Home Group Plc - Strategy, SWOT and Corporate Finance Report Summary Pets at Home Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆